このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Genetron Holdings 過去の業績

過去基準チェック /06

Genetron Holdingsの収益は年間平均-62.9%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間15.5% 22.3%割合で増加しています。

主要情報

-62.9%

収益成長率

-61.7%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	22.3%
株主資本利益率	-147.8%
ネット・マージン	-124.2%
前回の決算情報	31 Dec 2022

Recent updates

Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price

Aug 17

Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

Mar 27

Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?

Feb 25

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

Jan 06

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China

Nov 27

Genetron (GTH) Investor Presentation - Slideshow

Nov 18

Genetron Holdings reports Q3 results

Nov 09

収支内訳

Genetron Holdings の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGM:GTH 収益、費用、利益 ( )CNY Millions
日付	収益	収益	G+A経費	研究開発費
31 Dec 22	651	-808	690	290
30 Sep 22	596	-772	695	301
30 Jun 22	547	-701	656	289
31 Mar 22	550	-558	644	284
31 Dec 21	532	-496	607	254
30 Sep 21	519	-407	521	221
30 Jun 21	478	-326	457	198
31 Mar 21	440	-3,066	417	171
31 Dec 20	424	-3,069	388	149
30 Sep 20	393	-3,131	355	128
30 Jun 20	363	-3,357	361	111
31 Mar 20	334	-660	365	100
31 Dec 19	323	-676	373	92
30 Sep 19	294	-666	366	80
31 Dec 18	225	-465	271	71
31 Dec 17	101	-421	140	46

質の高い収益: GTHは現在利益が出ていません。

利益率の向上: GTHは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: GTHの過去 5 年間の前年比収益成長率がプラスであったかどうかを判断するにはデータが不十分です。

成長の加速: GTHの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: GTHは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: GTHは現在利益が出ていないため、自己資本利益率 ( -147.83% ) はマイナスです。

Genetron Holdings 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Second quarter 2022 earnings released: CN¥2.54 loss per share (vs CN¥1.00 loss in 2Q 2021)

Genetron Holdings Limited to Report Q1, 2022 Results on Jun 02, 2022

Full year 2021 earnings: EPS misses analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations

Genetron Holdings Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2021

Recent updates

Genetron Holdings Files Form 15

Genetron Holdings Requests Nasdaq to File Form 25 with the Securities and Exchange Commission for Delisting of the ADSs on Nasdaq and the Deregistration of its Registered Securities

New minor risk - Shareholder dilution

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Genetron Health Regains Compliance with Nasdaq Minimum Bid Price Requirement

Less than half of directors are independent

Genetron Health Announces Receipt of Notification from Nasdaq Regarding Minimum Bid Price

Second quarter 2022 earnings released: CN¥2.54 loss per share (vs CN¥1.00 loss in 2Q 2021)

Genetron Holdings GAAP EPS of -$0.08, revenue of $20.56M

Sizhen Wang made a non binding proposal to acquire the remaining 49.2% stake in Genetron Holdings Limited (NasdaqGM:GTH) from Genetron Health (Hong Kong) Company Limited and others for $60 million.

China's Genetron gets acquisition offer from co-founder/CEO

Genetron Holdings Limited to Report Q1, 2022 Results on Jun 02, 2022

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to US$6.51

Consensus EPS estimates fall by 24%

Less than half of directors are independent

Consensus EPS estimates fall by 24%

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations

Genetron Holdings Limited Reports Impairment Charges for the Fourth Quarter Ended December 31, 2021

Genetron Holdings Limited Reiterates Full Year 2021 Revenue Guidance

Chief Technology Officer notifies of intention to sell stock

Chief Financial Officer notifies of intention to sell stock

Are Investors Undervaluing Genetron Holdings Limited (NASDAQ:GTH) By 27%?

Chief Financial Officer notifies of intention to sell stock

Third quarter 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$18.92

Genetron Holdings Limited Provides Revenue Guidance for the Full Year 2021

Price target decreased to US$22.63

Co-Founder notifies of intention to sell stock

Second quarter 2021 earnings released

Genetron Holdings Limited Maintains Revenue Guidance for the Year 2021

Genetron Holdings Limited's (NASDAQ:GTH) Intrinsic Value Is Potentially 24% Below Its Share Price

Genetron Health Limited Receives CE Mark for 8-Gene Lung Cancer Assay and Provides FDA Reference Panel Comparative Data of its SARS-CoV-2 RNA Test

Chief Operating Officer Ying Hong has left the company

Non-Executive Director Weidong Liu has left the company

Genetron Holdings Limited Reiterates 2021 Financial Guidance

First quarter 2021 earnings released: CN¥1.23 loss per share (vs CN¥4.62 loss in 1Q 2020)

Full year 2020 earnings released: CN¥50.92 loss per share (vs CN¥27.06 loss in FY 2019)

Consensus forecasts updated

Genetron Holdings Limited (NASDAQ:GTH) Released Earnings Last Week And Analysts Lifted Their Price Target To US$26.22

Genetron Holdings Limited Provides Revenue Guidance for Year 2021

Full year 2020 earnings released: CN¥50.92 loss per share (vs CN¥27.06 loss in FY 2019)

Genetron Holdings Limited to Report Q4, 2020 Results on Mar 25, 2021

Is Genetron Holdings Limited (NASDAQ:GTH) Popular Amongst Insiders?

New 90-day high: US$28.04

New 90-day high: US$23.47

Genetron Health Announces Exclusive Strategic Partnership with Chia Tai Tianqing Pharmaceutical Group Co., Ltd

Genetron Health, Sino Biopharm's subsidiary inks strategic partnership for HCCscreen in China

New 90-day high: US$14.00

Genetron Holdings Limited Provides an Update for Hccscreentm, Its Blood-Based Early Screening Test for Hepatocellular Carcinoma (“Hcc”), in China

Genetron up 2% after HCCscreen selected by NCC, Wuxi for public health initiative in China

New 90-day high: US$13.27

Genetron (GTH) Investor Presentation - Slideshow

Analysts increase EPS estimates to -CN¥10.14

Genetron Holdings reports Q3 results

Genetron Holdings Limited to Report Q3, 2020 Results on Nov 09, 2020

Genetron Holdings Limited Receives U.S. FDA Breakthrough Device Designation for its Blood-based NGS Test for Early Detection of Hepatocellular Carcinoma

Genetron Holdings Limited and Cstone Pharmaceuticals Announce Launch of Clinical Trial in China for Companion Diagnostic Test in Development for Avapritinib

New 90-day low: US$10.80

Genetron Health and Dmed Announce Partnership Agreement

First half earnings released

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去の収益成長分析

株主資本利益率

過去基準チェック /06